HDAC4 and head and neck cancer: Taken together, neither HDAC4 nor HDAC5 expression status nor class IIa HDAC inhibition had a notable influence on cisplatin sensitivity in the head and neck cancer cell lines Cal27 and Cal27CisR (shift factors < 2) in contrast to results with vorinostat (Table 5).